Generation Bio

Generation Bio Stock-Based Compensation

Delisted

The Stock-Based Compensation (SBC) of Generation Bio (GBIO) as of Nov 10, 2026 is 14.61 M USD. In the previous year, Stock-Based Compensation (SBC) was 24.34 M USD — a change of -39.98% (lower).

Stock-Based Compensation

14.61 MUSD

YoY

-39.98%

Last updated:

Stock-Based Compensation (SBC) of Generation Bio is 2024 14.61 M USD. Stock-Based Compensation (SBC) of Generation Bio was 2023 24.34 M USD. It decreases by -39.98% lower compared to the previous year.

The Generation Bio Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
3.49 M USD
Jan 1, 2019
4.21 M USD
Jan 1, 2020
8.41 M USD
Jan 1, 2021
17.86 M USD
Jan 1, 2022
24.45 M USD
Jan 1, 2023
24.34 M USD
Jan 1, 2024
14.61 M USD
The Generation Bio Stock-Based Compensation history
YEARStock-Based CompensationYoY
14.61 MUSD-39.98%
24.34 MUSD-0.45%
24.45 MUSD+36.93%
17.86 MUSD+112.28%
8.41 MUSD+99.95%
4.21 MUSD+20.61%
3.49 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

Stock-Based Compensation (SBC) of Generation Bio is 14.61 M USD in 2024.

Stock-Based Compensation (SBC) of Generation Bio changed from 24.34 M USD to 14.61 M USD, representing a -39.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Generation Bio since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Generation Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Generation Bio

All Key Metrics — Generation Bio